Investigation of the rs28371759 polymorphism of CYP3A4 gene in Guangdong population

Abstract

Abstract: AIM: To study the genotype distribution of rs28371759(20070T>C) polymorphism of CYP3A4 in Guangdong population and to supply reference information for clinical safe medication of drugs metabolized by CYP3A4. METHODS: Taking 200 Guangdong volunteers' buccal swabs DNA as templates, then the DNA fragments encompassing the rs28371759 polymorphic locus were amplified by polymerase chain reaction,the amplified products were subjected to restriction enzyme analysis with MspI, then the digested products were subjected to polyacrylamide gel electrophoresis and sliver-staining, restriction enzyme maps derived were used for determining the corresponding genotypes.RESULTS: Among these detected 200 samples, heterozygotes were found in 3 cases, while the others were wild-types. The wild homozygotes, heterozygotes, mutant homozygotes were 0.985, 0.015, 0 respectively. The frequency of mutant allele 20070C was 0.0075.CONCLUSION: This research shows distribution of CYP3A4 gene rs28371759 polymorphism locus in Guangdong population, which lay a foundation for researching the relationship between CYP3A4 gene polymorphism and clinical drug effect.

Key words: Guangdong population, CYP3A4^*18A, polymorphism

CLC Number:

R968

WANG Rong, CHEN Ke-rui, LIU Xiao-mei, TANG Hui-en, HE Zhen-yu. Investigation of the rs28371759 polymorphism of CYP3A4 gene in Guangdong population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1255-1258.

References 12

[1]	陈欣,李玉珍,方翼. CYP3A4代谢药物的特点及其多态性的研究现状[J]. 中国药房, 2010,21(22):2097-2099.
[2]	李赟, 何芳, 曾彩雯,等. CYP2C9、CYP2C19、CYP3A4基因多态性对磺脲类降糖药代谢的影响[J]. 中国临床药理学与治疗学, 2012, 17(5):582-587.
[3]	He BX, Shi L, Qiu J, et al.A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population[J]. Basic Clin Pharmacol Toxicol, 2011, 108(3):208-213.
[4]	Maekawa K, Harakawa N, Yoshimura T, et al.CYP3A416 and CYP3A418 alleles found in east asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs[J]. Drug Metab Dispos, 2010, 38(12):2100-2104.
[5]	Tsai SM, Lin CY, Wu SH, et al.Hou.Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms[J]. Clin Chim Acta, 2009, 404(2):160-165.
[6]	李艳梅. 西南地区儿童CYP3A4基因多态性分析与耐药性癫痫相关性研究[D].重庆:重庆医科大学,2012:1-45.
[7]	Lee SJ, Lee SS, Jeong HE, et al.The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals[J]. Drug Metab Dispos, 2007, 35(11):2095-2101.
[8]	Kang YS,Park SY,Yim CH,et al.The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density[J]. Clin Pharmacol Ther, 2009, 85(3):312-318.
[9]	Dai D, Tang J, Rose R, et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos[J]. J Pharmacol Exp Ther, 2001, 299(3):825-831.
[10]	孙强. 中国维吾尔族人群细胞色素酶CYP450 3A4的遗传多态性探索和分析[D].西安:西北大学,2012:1-63.
[11]	Hu YF, He J, Chen GL, et al.CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population[J]. Clinica Chimica Acta, 2005, 353(1/2):187-192.
[12]	Hsieh KP, Lin YY, Cheng CL,et al.Novel mutations of CYP3A4 in Chinese[J]. Drug Metab Dispos, 2001, 29(3):268-273.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[4]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[5]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[6]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[7]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[8]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[9]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[10]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[11]	ZHOU Minmin, YU Lu, HAN Chao, GU Damin, LEI Daoyun. Relationship between human cholesteryl ester transfer protein rs5882 gene polymorphism and postoperative cognitive dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 768-774.
[12]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[13]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[14]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[15]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.